Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic" is generating significant coverage in the Business category, with 11 articles from 9 distinct sources tracked by PULSE so far.
Outlets currently covering the story include BioSpace, Yahoo Finance, kalkine.ca and FirstWord Pharma. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 11d ago.
Quick answers
Why is "Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic" trending?
Because 9 independent news sources published 11 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (11)
- Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’ BioSpace · 13d ago
- Nurix Therapeutics stock tumbles on Sanofi program termination Yahoo Finance · 13d ago
- Why Are Nurix (NASDAQ:NRIX), Supernus (NASDAQ:SUPN), UroGen (NASDAQ:URGN) and Cerenome (NASDAQ:CNSY) Falling? kalkine.ca · 13d ago
- Nurix's stock craters after Sanofi bins STAT6 degrader FirstWord Pharma · 13d ago
- Why Is Nurix Therapeutics (NASDAQ:NRIX) Down 40.80% Even With a USD 700 Million Roche Payment? kalkine.ca · 13d ago
- Sanofi stops development of Nurix-partnered immune drug BioPharma Dive · 13d ago
- Sanofi Breaks Out; Why Its Eczema Partner Just Crashed Investor's Business Daily · 13d ago
- Nurix stock falls as Sanofi scraps partnered drug (NRIX:NASDAQ) Seeking Alpha · 13d ago
- Nurix says Sanofi discontinues autoimmune disease drug program Reuters · 13d ago
- Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272 Yahoo Finance · 13d ago
- Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic Fierce Biotech · 13d ago
Topics
Related trends
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Seawolf Therapeutics launches with $100 million from Versant Ventures and Eli Lilly to develop non-viral gene therapies targeting obesity, muscle loss, and osteoporosis.
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
Sanofi and Regeneron have deepened their immunology alliance in a deal worth up to $8 billion to secure early-stage assets and a Dupixent successor.
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi is scrapping plans for an eczema drug derived from its billion-dollar Kymab acquisition following a strategic pipeline review.
Johns Hopkins surgeon highlights AI breakthrough that could spot pancreatic cancer before doctors
A Johns Hopkins surgeon reveals an AI breakthrough capable of detecting pancreatic cancer earlier than human physicians.
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
Sanofi's Sarclisa becomes the first cancer drug to receive FDA approval for delivery via a wearable on-body injector for multiple myeloma patients.
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
AstraZeneca and Sanofi detail new respiratory clinical data at the #ERS26 conference.